Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165442 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12281621 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12165436 | 0.83 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL1699450 | 0.83 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL13352355 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL2639282 | 0.82 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Hydrochloric Acid SCHEMBL3925422 | 0.82 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10613798 | 0.82 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL4560773 | 0.81 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL12165451 | 0.80 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SUNOVION PHARMACEUTICALS INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-9072700-B2 | Methods of using derivatives of (−)-venlafaxine | SUNOVION PHARMACEUTICALS INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8642662-B2 | Methods of using derivatives of (−)-venlafaxine | SUNOVION PHARMACEUTICALS INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120232157-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | JERUSSI THOMAS P (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232157-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | COMT, MAOA, MAOB | SLC6A2 4/4885SLC6A4 10/4885SLC6A3 5/4885 |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | COMT, MAOA, MAOB | SLC6A2 4/4885SLC6A4 11/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.